![]() |
市场调查报告书
商品编码
1642689
2025-2033 年粪便隐匿测试市场报告(按测试类型、最终用户和地区划分)Fecal Occult Testing Market Report by Test Type, End User, and Region 2025-2033 |
2024年,全球粪便隐匿检测市场规模达14.269IMARC Group美元。大肠直肠癌盛行率的上升、非侵入性检测技术的显着进步、意识和筛检计划的提高、政府对早期癌症检测和预防的倡议不断增加以及人口老化是推动市场增长的一些主要因素。
粪便潜血检查 (FOBT) 是一种非侵入性程序,用于检测粪便或粪便中隐藏的血液。它是透过使用卡片和可冲洗试剂垫或纸巾收集样本来执行的。这些样本被送到实验室进行检测,用于诊断痔疮、憩室病、溃疡、结肠炎、良性肿瘤和结肠息肉或癌症等导致消化道出血的疾病。目前,人们对早期筛检的认识不断增强,正在推动粪便隐匿性检测的采用,因为它可以快速做出医疗决策,提供有效的医疗保健,并提高生活品质并降低死亡率。
人们越来越关注改善患者体验和健康结果的全面医疗服务,再加上人们越来越倾向于床边诊断 (POCD),这是刺激市场成长的关键因素之一。除此之外,随着感染疾病的风险随着年龄的增长而增加,老年人口的增加正在加速市场的成长。因此,各国管理机构正在实施多项针对老年人的 FOBT 筛检计画。此外,微创(MI)手术的广泛采用也促进了市场的成长。除此之外,免疫化学粪便潜血检查(iFOBT 或 FIT)越来越受到关注,因为它们易于使用,并且在临床上对癌症和晚期腺瘤更敏感。 FOBT 设备在线上零售商店的便利供应预计将对未来几年的市场成长产生正面影响。
癒创木脂 FOB 粪便测试
免疫 FOB 凝集试验
侧流免疫 FOB 测试
免疫 FOB ELISA 测试
医院
临床诊断实验室
医师办公室实验室
北美洲
美国
加拿大
亚太
中国
日本
印度
韩国
澳洲
印尼
其他的
欧洲
德国
法国
英国
义大利
西班牙
俄罗斯
其他的
拉丁美洲
巴西
墨西哥
其他的
中东和非洲
也审查了该行业的竞争格局以及主要参与者的概况,包括 Abbott Laboratories、Beckman Coulter Inc.(Danaher Corporation)、Biohit Oyj、EDP Biotech Corporation、Eiken Chemical Co. Ltd.、Epigenomics AG、Quest Diagnostics Quidel Corporation 和Randox Laboratories Ltd. 成立
The global fecal occult testing market size reached USD 1,426.9 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,142.2 Million by 2033, exhibiting a growth rate (CAGR) of 4.15% during 2025-2033. The rising prevalence of colorectal cancer, significant advancements in non-invasive testing technologies, increasing awareness and screening programs, growing government initiatives for early cancer detection and prevention, and rising aging populations are some of the major factors propelling the market growth.
A fecal occult blood test (FOBT) is a noninvasive procedure used to detect hidden blood in the feces or stool. It is performed by collecting samples using cards and flushable reagent pads or tissues. These samples are sent to the laboratory for testing and are used to diagnose conditions such as hemorrhoids, diverticulosis, ulcers, colitis, benign tumors and colon polyps or cancer, which cause bleeding in the digestive tract. At present, the growing awareness about early screening is promoting the adoption of fecal occult testing, as it enables quick medical decisions, provides effective healthcare, and leads to improved quality of life and the reduced mortality rate.
The rising focus on integrated health services for improved patient experience and health outcomes, in confluence with the increasing inclination towards point-of-care diagnostics (POCD), represents one of the key factors stimulating the market growth. Apart from this, the rising geriatric population is accelerating the growth of the market as the risk of contracting diseases increases with age. As a result, governing agencies of various countries are implementing several FOBT screening programs for older adults. Furthermore, the widespread adoption of minimally invasive (MI) procedures is contributing to the growth of the market. Besides this, immunochemical fecal occult blood tests (iFOBTs or FITs) are gaining traction as they are easy to use and clinically more sensitive to cancers and advanced adenomas. The easy availability of FOBT devices at online retail stores is anticipated to create a positive impact on the market growth in the upcoming years.
Guaiac FOB Stool Test
Immuno-FOB Agglutination Test
Lateral Flow Immuno-FOB Test
Immuno-FOB ELISA Test
Hospitals
Clinical Diagnostic Laboratories
Physician Office Laboratories
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Beckman Coulter Inc. (Danaher Corporation), Biohit Oyj, EDP Biotech Corporation, Eiken Chemical Co. Ltd., Epigenomics AG, Quest Diagnostics Incorporated, Quidel Corporation and Randox Laboratories Ltd.